1. Home
  2. RIGL vs TCI Comparison

RIGL vs TCI Comparison

Compare RIGL & TCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • TCI
  • Stock Information
  • Founded
  • RIGL 1996
  • TCI 1983
  • Country
  • RIGL United States
  • TCI United States
  • Employees
  • RIGL N/A
  • TCI N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • TCI Real Estate
  • Sector
  • RIGL Health Care
  • TCI Finance
  • Exchange
  • RIGL Nasdaq
  • TCI Nasdaq
  • Market Cap
  • RIGL 335.5M
  • TCI 357.8M
  • IPO Year
  • RIGL 2000
  • TCI N/A
  • Fundamental
  • Price
  • RIGL $38.85
  • TCI $45.60
  • Analyst Decision
  • RIGL Buy
  • TCI
  • Analyst Count
  • RIGL 5
  • TCI 0
  • Target Price
  • RIGL $38.20
  • TCI N/A
  • AVG Volume (30 Days)
  • RIGL 995.6K
  • TCI 1.8K
  • Earning Date
  • RIGL 08-05-2025
  • TCI 08-07-2025
  • Dividend Yield
  • RIGL N/A
  • TCI N/A
  • EPS Growth
  • RIGL N/A
  • TCI 11.20
  • EPS
  • RIGL 5.43
  • TCI 0.76
  • Revenue
  • RIGL $267,921,000.00
  • TCI $47,730,000.00
  • Revenue This Year
  • RIGL $59.93
  • TCI N/A
  • Revenue Next Year
  • RIGL N/A
  • TCI N/A
  • P/E Ratio
  • RIGL $7.15
  • TCI $61.66
  • Revenue Growth
  • RIGL 105.62
  • TCI N/A
  • 52 Week Low
  • RIGL $12.66
  • TCI $25.50
  • 52 Week High
  • RIGL $43.72
  • TCI $48.00
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 68.57
  • TCI 56.33
  • Support Level
  • RIGL $39.00
  • TCI $46.00
  • Resistance Level
  • RIGL $42.08
  • TCI $48.00
  • Average True Range (ATR)
  • RIGL 2.32
  • TCI 0.80
  • MACD
  • RIGL -0.37
  • TCI 0.05
  • Stochastic Oscillator
  • RIGL 53.26
  • TCI 67.90

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About TCI Transcontinental Realty Investors Inc.

Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.

Share on Social Networks: